387 related articles for article (PubMed ID: 17622758)
1. The effect of mild hyperuricemia on urinary transforming growth factor beta and the progression of chronic kidney disease.
Talaat KM; el-Sheikh AR
Am J Nephrol; 2007; 27(5):435-40. PubMed ID: 17622758
[TBL] [Abstract][Full Text] [Related]
2. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level.
Siu YP; Leung KT; Tong MK; Kwan TH
Am J Kidney Dis; 2006 Jan; 47(1):51-9. PubMed ID: 16377385
[TBL] [Abstract][Full Text] [Related]
3. Relationship between hyperuricemia and chronic kidney disease.
Ohno I
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1039-44. PubMed ID: 22132954
[TBL] [Abstract][Full Text] [Related]
4. [The relationship between the gene polymorphism of TGF-beta1 and early renal injury in patients with essential hypertension, and the effect of the gene polymorphism of TGF- beta1 on the individual treatment with valsartan].
Zhao C; Wang YY; Xiao ZX; Wang YP; Zhang QY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):428-31. PubMed ID: 17680535
[TBL] [Abstract][Full Text] [Related]
5. Serum uric acid levels and renal damage in hyperuricemic hypertensive patients treated with renin-angiotensin system blockers.
Berni A; Boddi M; Fattori EB; Cecioni I; Berardino S; Montuschi F; Chiostri M; Poggesi L
Am J Hypertens; 2010 Jun; 23(6):675-80. PubMed ID: 20203626
[TBL] [Abstract][Full Text] [Related]
6. Transforming growth factor-beta1 is associated with kidney damage in patients with essential hypertension: renoprotective effect of ACE inhibitor and/or angiotensin II receptor blocker.
Zhu S; Liu Y; Wang L; Meng QH
Nephrol Dial Transplant; 2008 Sep; 23(9):2841-6. PubMed ID: 18390891
[TBL] [Abstract][Full Text] [Related]
7. Antifibrotic effects of aldosterone receptor blocker (spironolactone) in patients with chronic kidney disease.
Guney I; Selcuk NY; Altintepe L; Atalay H; Başarali MK; Büyükbaş S
Ren Fail; 2009; 31(9):779-84. PubMed ID: 19925284
[TBL] [Abstract][Full Text] [Related]
8. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
Furumatsu Y; Nagasawa Y; Tomida K; Mikami S; Kaneko T; Okada N; Tsubakihara Y; Imai E; Shoji T
Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
[TBL] [Abstract][Full Text] [Related]
9. Worsening renal failure in older chronic kidney disease patients with renal artery stenosis concurrently on renin angiotensin aldosterone system blockade: a prospective 50-month Mayo-Health-System clinic analysis.
Onuigbo MA; Onuigbo NT
QJM; 2008 Jul; 101(7):519-27. PubMed ID: 18375475
[TBL] [Abstract][Full Text] [Related]
10. Can we slow the progression of chronic kidney disease?
Wühl E; Schaefer F
Curr Opin Pediatr; 2010 Apr; 22(2):170-5. PubMed ID: 20042976
[TBL] [Abstract][Full Text] [Related]
11. [Urine excretion of a monocytic chemotaxic protein-1 and a transforming growth factor beta1 as an indicator of chronic glomerulonephritis progression].
Bobkova IN; Chebotareva NV; Kozlovskaia LV; Varshavskiĭ VA; Golitsyna EP
Ter Arkh; 2006; 78(5):9-14. PubMed ID: 16889042
[TBL] [Abstract][Full Text] [Related]
12. [Hypertension in patients with chronic renal disease].
Laville M
Rev Prat; 2004 Mar; 54(6):641-5. PubMed ID: 15222616
[TBL] [Abstract][Full Text] [Related]
13. Essential hypertension, progressive renal disease, and uric acid: a pathogenetic link?
Johnson RJ; Segal MS; Srinivas T; Ejaz A; Mu W; Roncal C; Sánchez-Lozada LG; Gersch M; Rodriguez-Iturbe B; Kang DH; Acosta JH
J Am Soc Nephrol; 2005 Jul; 16(7):1909-19. PubMed ID: 15843466
[TBL] [Abstract][Full Text] [Related]
14. Importance of blood pressure control in chronic kidney disease.
Ravera M; Re M; Deferrari L; Vettoretti S; Deferrari G
J Am Soc Nephrol; 2006 Apr; 17(4 Suppl 2):S98-103. PubMed ID: 16565257
[TBL] [Abstract][Full Text] [Related]
15. Effects of xanthine oxidase inhibitors on renal function and blood pressure in hypertensive patients with hyperuricemia.
Kohagura K; Tana T; Higa A; Yamazato M; Ishida A; Nagahama K; Sakima A; Iseki K; Ohya Y
Hypertens Res; 2016 Aug; 39(8):593-7. PubMed ID: 27075830
[TBL] [Abstract][Full Text] [Related]
16. Urinary kallikrein excretion is related to renal function change and inflammatory status in chronic kidney disease patients receiving angiotensin II receptor blocker treatment.
Chiang WC; Lin SL; Chen YM; Wu KD; Tsai TJ
Nephrology (Carlton); 2008 Jun; 13(3):198-203. PubMed ID: 18315702
[TBL] [Abstract][Full Text] [Related]
17. Hypersensitivity syndrome and pure red cell aplasia following allopurinol therapy in a patient with chronic kidney disease.
Chao SC; Yang CC; Lee JY
Ann Pharmacother; 2005 Sep; 39(9):1552-6. PubMed ID: 16076905
[TBL] [Abstract][Full Text] [Related]
18. Activation of ATP-sensitive potassium channels protects vascular endothelial cells from hypertension and renal injury induced by hyperuricemia.
Long CL; Qin XC; Pan ZY; Chen K; Zhang YF; Cui WY; Liu GS; Wang H
J Hypertens; 2008 Dec; 26(12):2326-38. PubMed ID: 19008712
[TBL] [Abstract][Full Text] [Related]
19. Effect of allopurinol on slowing allograft functional decline in kidney transplant recipients.
Osadchuk L; Bashir MH; Tangirala B; Marcus RJ; Nashar K; Hussain SM; Sureshkumar KK
Exp Clin Transplant; 2014 Jun; 12(3):190-4. PubMed ID: 24907717
[TBL] [Abstract][Full Text] [Related]
20. Uric acid in hypertension and renal disease: the chicken or the egg?
Kanbay M; Solak Y; Dogan E; Lanaspa MA; Covic A
Blood Purif; 2010; 30(4):288-95. PubMed ID: 21088389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
